Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Celldex Therapeutics (CLDX) over the last 10 years, with Q3 2025 value amounting to $66420.0.

  • Celldex Therapeutics' Shares Outstanding (Diluted Average) rose 19.01% to $66420.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $66420.0, marking a year-over-year increase of 19.01%. This contributed to the annual value of $64395.0 for FY2024, which is 3291.3% up from last year.
  • Latest data reveals that Celldex Therapeutics reported Shares Outstanding (Diluted Average) of $66420.0 as of Q3 2025, which was up 19.01% from $66392.0 recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $45.5 million in Q3 2021 and a low of $42870.0 during Q4 2021
  • Over the past 5 years, Celldex Therapeutics' median Shares Outstanding (Diluted Average) value was $58871.0 (recorded in 2024), while the average stood at $6.6 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 4463.56% in 2021, then plummeted by 9989.68% in 2022.
  • Celldex Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $42870.0 in 2021, then rose by 9.37% to $46888.0 in 2022, then increased by 3.33% to $48449.0 in 2023, then soared by 32.91% to $64395.0 in 2024, then grew by 3.14% to $66420.0 in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $66420.0 for Q3 2025, versus $66392.0 for Q2 2025 and $66383.0 for Q1 2025.